undamentalytics Newsletter
Sign in

Nurix Therapeutics, Inc. cash flow statement

In fiscal 2025, Nurix Therapeutics, Inc.'s operations generated −$249m of cash; it spent $14.0m on capital projects, leaving free cash flow of −$263m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Nov 20192020Nov 20202021Nov 20212022Nov 20222023Nov 20232024Nov 20242025Nov 2025LTMAug 2026
Cash from operations1−0−84−160−81−173−249379
Depreciation and amortisation22358999
Stock-based pay14162834343841
Capital spending25612891410
Free cash flow−1−5−90−172−90−182−263370
Free cash flow after stock pay−2−9−106−200−123−216−301329
Shares issued—218150190290018

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: NRIX vs RAREARWR vs NRIXMIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nurix Therapeutics, Inc.